Cardio Diagnostics Earnings Estimate
| CDIO Stock | USD 1.51 0.09 5.63% |
Cardio Diagnostics Earnings per Share Projection vs Actual
About Cardio Diagnostics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Cardio Diagnostics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Cardio Diagnostics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Cardio Diagnostics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -20.5 M | -19.5 M | |
| Earnings Yield | (0.01) | (0.01) | |
| Price Earnings Ratio | (79.42) | (83.39) | |
| Price Earnings To Growth Ratio | 1.50 | 1.57 |
Pair Trading with Cardio Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardio Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cardio Stock
| 0.61 | EVGN | Evogene | PairCorr |
| 0.67 | IMNN | Imunon Inc | PairCorr |
| 0.88 | LYRA | Lyra Therapeutics | PairCorr |
| 0.7 | MBIO | Mustang Bio | PairCorr |
Moving against Cardio Stock
| 0.75 | CING | Cingulate | PairCorr |
| 0.72 | MRKR | Marker Therapeutics | PairCorr |
| 0.63 | AEON | AEON Biopharma | PairCorr |
| 0.5 | BOLT | Bolt Biotherapeutics | PairCorr |
| 0.48 | ARWR | Arrowhead Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Cardio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardio Diagnostics Holdings to buy it.
The correlation of Cardio Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardio Diagnostics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Will Biotechnology sector continue expanding? Could Cardio diversify its offerings? Factors like these will boost the valuation of Cardio Diagnostics. Projected growth potential of Cardio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cardio Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (11.91) | Revenue Per Share | Quarterly Revenue Growth (0.57) | Return On Assets | Return On Equity |
Cardio Diagnostics's market price often diverges from its book value, the accounting figure shown on Cardio's balance sheet. Smart investors calculate Cardio Diagnostics' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cardio Diagnostics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cardio Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardio Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.